Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer

Professor of Cancer Biology



charlotte.bevan Website




Mrs Suzy Ford +44 (0)20 7594 2135




139ICTEM buildingHammersmith Campus






BibTex format

author = {Brooke, GN and Gamble, SC and Hough, MA and Begum, S and Dart, DA and Odontiadis, M and Powell, SM and Fioretti, FM and Bryan, RA and Waxman, J and Wait, R and Bevan, CL},
doi = {10.1074/mcp.M113.036764},
journal = {Molecular & Cellular Proteomics},
pages = {1201--1216},
title = {Antiandrogens act as selective androgen receptor modulators at the proteome Level in prostate cancer cells},
url = {},
volume = {14},
year = {2015}

RIS format (EndNote, RefMan)

AB - Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the androgen receptor, which repress androgen-stimulated growth. These include the selective androgen receptor modulators cyproterone acetate and hydroxyflutamide and the complete antagonist bicalutamide. Their activity is partly dictated by the presence of androgen receptor mutations, which are commonly detected in patients who relapse while receiving antiandrogens, i.e. in castrate-resistant prostate cancer. To characterize the early proteomic response to these antiandrogens we used the LNCaP prostate cancer cell line, which harbors the androgen receptor mutation most commonly detected in castrate-resistant tumors (T877A), analyzing alterations in the proteome, and comparing these to the effect of these therapeutics upon androgen receptor activity and cell proliferation. The majority are regulated post-transcriptionally, possibly via nongenomic androgen receptor signaling. Differences detected between the exposure groups demonstrate subtle changes in the biological response to each specific ligand, suggesting a spectrum of agonistic and antagonistic effects dependent on the ligand used. Analysis of the crystal structures of the AR in the presence of cyproterone acetate, hydroxyflutamide, and DHT identified important differences in the orientation of key residues located in the AF-2 and BF-3 protein interaction surfaces. This further implies that although there is commonality in the growth responses between androgens and those antiandrogens that stimulate growth in the presence of a mutation, there may also be influential differences in the growth pathways stimulated by the different ligands. This therefore has implications for prostate cancer treatment because tumors may respond differently dependent upon which mutation is present and which ligand is activating growth, also for the design of selective androgen receptor modulators, which aim to elicit differential proteomic responses
AU - Brooke,GN
AU - Gamble,SC
AU - Hough,MA
AU - Begum,S
AU - Dart,DA
AU - Odontiadis,M
AU - Powell,SM
AU - Fioretti,FM
AU - Bryan,RA
AU - Waxman,J
AU - Wait,R
AU - Bevan,CL
DO - 10.1074/mcp.M113.036764
EP - 1216
PY - 2015///
SN - 1535-9484
SP - 1201
TI - Antiandrogens act as selective androgen receptor modulators at the proteome Level in prostate cancer cells
T2 - Molecular & Cellular Proteomics
UR -
UR -
UR -
VL - 14
ER -